- Home
- PIII vs SLGL Comparison
PIII vs SLGL Comparison
Compare PIII & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- SLGL
- Stock Information
- Founded
- PIII 2015
- SLGL 1997
- Country
- PIII United States
- SLGL Israel
- Employees
- PIII N/A
- SLGL N/A
- Industry
- PIII Medical/Nursing Services
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- SLGL Health Care
- Exchange
- PIII Nasdaq
- SLGL Nasdaq
- Market Cap
- PIII 28.6M
- SLGL 69.1M
- IPO Year
- PIII N/A
- SLGL 2018
- Fundamental
- Price
- PIII $8.63
- SLGL $23.98
- Analyst Decision
- PIII Strong Buy
- SLGL
- Analyst Count
- PIII 3
- SLGL 0
- Target Price
- PIII $17.50
- SLGL N/A
- AVG Volume (30 Days)
- PIII 6.9K
- SLGL 33.1K
- Earning Date
- PIII 11-11-2025
- SLGL 11-14-2025
- Dividend Yield
- PIII N/A
- SLGL N/A
- EPS Growth
- PIII N/A
- SLGL N/A
- EPS
- PIII N/A
- SLGL N/A
- Revenue
- PIII $1,461,823,000.00
- SLGL $23,931,000.00
- Revenue This Year
- PIII N/A
- SLGL N/A
- Revenue Next Year
- PIII $9.46
- SLGL $31.17
- P/E Ratio
- PIII N/A
- SLGL N/A
- Revenue Growth
- PIII 4.20
- SLGL 264.86
- 52 Week Low
- PIII $5.80
- SLGL $4.01
- 52 Week High
- PIII $26.99
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- PIII 66.82
- SLGL 58.56
- Support Level
- PIII $8.46
- SLGL $23.13
- Resistance Level
- PIII $8.90
- SLGL $24.85
- Average True Range (ATR)
- PIII 0.32
- SLGL 2.36
- MACD
- PIII 0.01
- SLGL -0.43
- Stochastic Oscillator
- PIII 80.29
- SLGL 39.19
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.